Literature DB >> 12821480

Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages.

Cristina Seral1, Françoise Van Bambeke, Paul M Tulkens.   

Abstract

Using J774 macrophages, the intracellular activities of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) against Staphylococcus aureus (strain ATCC 25923) have been quantitatively assessed in a 24-h model. S. aureus was positively localized in phagolysosomes by confocal and electron microscopy, and extracellular growth was prevented with 0.5 mg of gentamicin/liter (1x MIC) in controls. When tested at extracellular concentrations equivalent to their maximum concentrations in human serum, all antibiotics except azithromycin caused a significant reduction of the postphagocytosis inoculum within 24 h, albeit to markedly different extents (telithromycin [2 mg/liter], 0.60 log; ciprofloxacin [4.3 mg/liter], 0.81 log; gentamicin [18 mg/liter], 1.21 log; moxifloxacin [4 mg/liter], 1.51 log; oritavancin [25 mg/liter], 3.49 log). Intracellular activities were not systematically related to drug accumulation (apparent cellular-to-extracellular concentration ratios in infected cells: ciprofloxacin, 3.2; gentamicin, 6.8; telithromycin, 8.7; moxifloxacin, 13.4; azithromycin, 50; oritavancin, 348). Intracellular activity was not directly correlated to extracellular activity as measured in broth. Conditions of pH 5 (i.e., mimicking that of phagolysosomes) markedly reduced the activity of gentamicin, azithromycin, and telithromycin (>or=32 x) and fairly extensively reduced that of ciprofloxacin and moxifloxacin (>or=4 x) but did not affect oritavancin activity. We conclude that the cellular accumulation of antibiotics is not the only parameter to take into account for intracellular activity but that local environmental conditions (such as pH) and other factors can also prove critical.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12821480      PMCID: PMC161849          DOI: 10.1128/AAC.47.7.2283-2292.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  58 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Authors:  D Bahl; D A Miller; I Leviton; P Gialanella; M J Wolin; W Liu; R Perkins; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

3.  A comparison of methods used for measuring the accumulation of quinolones by Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  P G Mortimer; L J Piddock
Journal:  J Antimicrob Chemother       Date:  1991-11       Impact factor: 5.790

4.  The new ketolide HMR3647 accumulates in the azurophil granules of human polymorphonuclear cells.

Authors:  C Miossec-Bartoli; L Pilatre; P Peyron; E N N'Diaye; V Collart-Dutilleul; I Maridonneau-Parini; A Diu-Hercend
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

5.  Antimicrobial activity and accumulation of moxifloxacin in quinolone-susceptible bacteria.

Authors:  L J Piddock; Y F Jin
Journal:  J Antimicrob Chemother       Date:  1999-05       Impact factor: 5.790

6.  In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.

Authors:  F Biavasco; C Vignaroli; R Lupidi; E Manso; B Facinelli; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

7.  Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus.

Authors:  B Al-Nawas; P M Shah
Journal:  J Antimicrob Chemother       Date:  1998-06       Impact factor: 5.790

8.  Intracellular survival of staphylococci.

Authors:  F A KAPRAL; M G SHAYEGANI
Journal:  J Exp Med       Date:  1959-07-01       Impact factor: 14.307

9.  Intracellular activity of vancomycin and Ly333328, a new semisynthetic glycopeptide, against methicillin-resistant Staphylococcus aureus.

Authors:  B al-Nawas; P M Shah
Journal:  Infection       Date:  1998 May-Jun       Impact factor: 3.553

10.  The survival of staphylococci within human leukocytes.

Authors:  D E ROGERS; R TOMPSETT
Journal:  J Exp Med       Date:  1952-02       Impact factor: 14.307

View more
  51 in total

1.  Intra- and extracellular activities of dicloxacillin and linezolid against a clinical Staphylococcus aureus strain with a small-colony-variant phenotype in an in vitro model of THP-1 macrophages and an in vivo mouse peritonitis model.

Authors:  Anne Sandberg; Sandrine Lemaire; Françoise Van Bambeke; Paul M Tulkens; Diarmaid Hughes; Christof von Eiff; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages.

Authors:  Sandrine Lemaire; Françoise Van Bambeke; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

3.  Sensitization of intracellular Salmonella enterica serovar Typhimurium to aminoglycosides in vitro and in vivo by a host-targeted antimicrobial agent.

Authors:  Jung-Hsin Lo; Samuel K Kulp; Ching-Shih Chen; Hao-Chieh Chiu
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

Review 4.  Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?

Authors:  Alejandro Beceiro; María Tomás; Germán Bou
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

5.  Comparative activities of antibiotics against intracellular non-typeable Haemophilus influenzae.

Authors:  Christina Kratzer; Wolfgang Graninger; Karin Macfelda; Astrid Buxbaum; Apostolos Georgopoulos
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 6.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains.

Authors:  Hoang Anh Nguyen; Olivier Denis; Anne Vergison; Anne Theunis; Paul M Tulkens; Marc J Struelens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

8.  Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Authors:  Sandrine Lemaire; Youri Glupczynski; Valérie Duval; Bernard Joris; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

Review 9.  Glycopeptide antibiotics: from conventional molecules to new derivatives.

Authors:  Françoise Van Bambeke; Yves Van Laethem; Patrice Courvalin; Paul M Tulkens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Radha K Shandil; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharath; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.